BCNP1 CRISPR Activation Plasmid (h): sc-404731-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BCNP1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- BCNP1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by BCNP1 CRISPR Activation Plasmid (h) and BCNP1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the FAM129C transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BCNP1 CRISPR Activation Plasmid (h) | sc-404731-ACT | 20 µg | $397.00 |
FAM129C encodes BCNP1, an intracellular protein implicated in signaling and transcriptional programs that shape immune cell state and stress-adaptive responses. Expression of FAM129C is enriched in hematopoietic lineages and has been linked to modulation of inflammatory signaling and receptor-driven pathways that influence cell survival and differentiation. Altered BCNP1 expression has been reported across immune-associated conditions and multiple cancer contexts, supporting its utility as a molecular handle for studying lineage plasticity and tumor–immune interactions. As a result, FAM129C serves as a useful node for interrogating pathway rewiring in immunity, proliferation, and cellular stress biology in human model systems.
BCNP1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FAM129C expression without altering the underlying DNA sequence.
BCNP1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FAM129C locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FAM129C transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous BCNP1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FAM129C locus and enabling the study of BCNP1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of BCNP1 pathway restoration in tumor cells with silenced or reduced FAM129C expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.